BSE Live
Apr 17, 16:01Prev. Close
4869.25
Open Price
4869.25
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 17, 15:59Prev. Close
4859.20
Open Price
4864.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
4960.70 (10)
| Profit & Loss account of Pfizer (in Rs. Cr.) | Nov 08 | Nov 07 | Nov 06 | |
| 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||
| Revenue From Operations [Gross] | 790.92 | 798.57 | 796.72 | |
| Less: Excise/Sevice Tax/Other Levies | 57.72 | 62.97 | 63.02 | |
| Revenue From Operations [Net] | 733.20 | 735.60 | 733.70 | |
| Total Operating Revenues | 733.20 | 735.60 | 733.70 | |
| Other Income | 66.02 | 319.87 | 33.47 | |
| Total Revenue | 799.22 | 1,055.47 | 767.17 | |
| EXPENSES | ||||
| Cost Of Materials Consumed | 196.35 | 149.36 | 139.23 | |
| Purchase Of Stock-In Trade | 74.96 | 89.59 | 107.45 | |
| Operating And Direct Expenses | 30.99 | 29.05 | 26.80 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -22.49 | 4.77 | -10.25 | |
| Employee Benefit Expenses | 102.10 | 101.70 | 102.34 | |
| Finance Costs | 0.00 | 0.02 | 0.07 | |
| Depreciation And Amortisation Expenses | 11.12 | 9.58 | 13.07 | |
| Other Expenses | 198.86 | 204.64 | 202.44 | |
| Total Expenses | 591.89 | 588.70 | 581.16 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 207.33 | 466.76 | 186.01 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 207.33 | 466.76 | 186.01 | |
| Tax Expenses-Continued Operations | ||||
| Current Tax | 124.62 | 107.54 | 58.57 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -7.35 | 1.38 | -5.33 | |
| Other Direct Taxes | 2.28 | 2.42 | 3.07 | |
| Total Tax Expenses | 119.56 | 111.34 | 56.31 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 87.77 | 355.42 | 129.70 | |
| Profit/Loss From Continuing Operations | 299.57 | 340.00 | 106.33 | |
| Profit/Loss For The Period | 299.57 | 340.00 | 106.33 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | |
| Consolidated Profit/Loss After MI And Associates | 299.57 | 340.00 | 106.33 | |
| OTHER ADDITIONAL INFORMATION | ||||
| EARNINGS PER SHARE | ||||
| Basic EPS (Rs.) | 100.00 | 114.00 | 36.00 | |
| Diluted EPS (Rs.) | 100.00 | 114.00 | 36.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||
| Equity Share Dividend | 37.30 | 82.06 | 67.14 | |
| Tax On Dividend | 6.34 | 13.95 | 9.42 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth